Cycloheximide (CHX) treatment showed that CCAR2 protein degraded more slowly in BRCC3-overexpressing HCC cells, whereas BRCC3 knockdown accelerated degradation (Figure 5C). The gene discussed is BRCC3; the disease is hepatocellular carcinoma.